Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Duvelisib and Acalabrutinib in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (DUAL Trial)

NCT04836832 is registered in ClinicalTrials.gov with Narendranath Epperla as lead sponsor.

NCT NCT04836832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04836832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Duvelisib and Acalabrutinib in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (DUAL Trial)
Lead sponsor
Narendranath Epperla
Phase
Phase 1
Overall status
Withdrawn
Start date
July 1, 2022
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent follicular lymphoma, recurrent marginal zone lymphoma, recurrent nodal marginal zone lymphoma, recurrent splenic marginal zone lymphoma, refractory follicular lymphoma, refractory indolent non-hodgkin lymphoma, refractory marginal zone lymphoma, refractory nodal marginal zone lymphoma, refractory splenic marginal zone lymphoma